Collectively, these approaches support the advancement of ATR–CHK1 inhibitors from experimental agents to clinically viable tools for overcoming resistance and improving outcomes in biomarker-defined subsets of gastric cancer (Figure 4). This evidence concerns the gene ATR and gastric cancer.